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West Nile Virus,
Venezuela 
To the Editor: West Nile virus
(WNV; genus Flavivirus; family
Flaviviridae) has been perpetuating in
North America since 1999 (1).
However, its status as a self-perpetu-
ating pathogen in South America
remains uncertain. Infected horses
and birds have been reported in vari-
ous Caribbean Islands, Mexico, and
northern Central America (2,3). In
South America, isolated reports of
infected dead-end hosts (horses) have
come from northern Colombia and
Argentina, but they lack evidence for
infection in avian amplifying hosts
(4,5). We report serologic evidence of
establishment of WNV in South
America.
Serum samples from birds and
horses from 33 locations in
Venezuela (Online Appendix Table,
available from http://www.cdc.gov/
EID/content/13/4/651-appT.htm)
were screened for immunoglobulin G
(IgG) antibodies against WNV anti-
gen by ELISA (6) and confirmed by
plaque  reduction neutralization test
(PRNT) as previously described (7).
The flavivirus generating the IgG
response was identified by using the
following criteria: 90% inhibition of
virus in serum diluted at least 1:40
and 4-fold greater neutralizing anti-
body titer compared with closely
related flaviviruses. IgG antibody
against flavivirus was detected by
ELISA in 14 of 576 resident birds,
including 5 Turdus leucomelas, 3
Gallus gallus (captive), 2 Campylor-
hamphus trochilirostris, and 1 each of
Elaenia flavogaster, Coereba flaveo-
la, Thraupis palmarum, and Anisog-
nathus flavinucha. 
WNV was confirmed as the etio-
logic agent of infection in 5 adult
birds (3 T. leucomelas [pale-breasted
thrush], 1 C.  flaveola [bananaquit],
and 1 G.  gallus [domestic chicken]
with the earliest collection date in
February 2006); virus neutralization
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Figure. Temperature and heart rate relationship: scatter plot for patients with dengue fever
and nondengue febrile illnesses.LETTERS
titers ranged from 80 to 320. One
serum sample cross-reacted with
other flaviviruses tested, with equiva-
lent titers to WNV, Saint Louis
encephalitis virus (SLEV), and Ilheus
virus (ILHV) and was thus considered
infected with an undetermined fla-
vivirus. Seven serum samples were
negative (antibody titers <20), and 1
sample was not tested because of
insufficient sample volume.
Antibody against flavivirus was
detected by ELISAin 141 of 791 hors-
es, and 34 (4.3%) were confirmed pos-
itive for WNV infection by PRNT;
viral titers ≥640 occurred in half of
these horses. The earliest collection
date for a WNV-positive horse was
February 2004 and the most recent
was May 2006. Specific WNV-reac-
tive equine serum samples were dis-
tributed in valley regions (prevalence
1.3%), savannah grasslands (2.4%),
the western region of Zulia (0.4%) and
the Central Lake Basin (0.3%). A total
of 46 (5.8%) equine serum samples
were positive for neutralizing antibody
to SLEV, and 8 (1.0%) samples were
positive for neutralizing antibodies to
ILHV. Forty-nine samples neutralized
at least 2 of the 3 viruses and were
classified as undetermined flavivirus-
es. Serum samples from 2 horses were
negative in neutralization assays; 2
others were not tested because of
insufficient sample volume.
Detection of WNV-infected resi-
dent birds provides strong evidence of
the establishment, rather than impor-
tation, of WNV in South America. We
hypothesize that ornithophilic mos-
quitoes (such as some Culex spp.),
which are present in the area in con-
sistently high numbers, acquired the
virus through hematophagous feeding
on recently infected, migrating birds.
Once introduced to local mosquitoes,
virus is amplified among susceptible
resident birds fed upon by ornitho-
philic mosquitoes. This pattern allows
perpetuation and subsequent estab-
lishment of virus in a continuous
transmission cycle, as opposed to
infection of dead-end hosts, e.g., hors-
es. This is the first report of WNV
infection in South American birds and
definitive establishment of the virus
in South America.
We observed varying WNV sero-
prevalence rates in birds and horses
across regions in Venezuela (Figure).
These differences reflect the focal and
stochastic nature of arbovirus trans-
mission, which depends upon many
ecologic factors. One possible expla-
nation for the greater seroprevalence
in the central and eastern llanos
(savannahs) and valley regions, com-
pared with the coastal western region
of Zulia State (p<0.0001, by
Pearson’s  χ2 test) would be virus
introduction by migrating birds by an
eastern migration route.
Existence of several closely relat-
ed flaviviruses in the American trop-
ics (8–10) may convey cross-protec-
tion in animals (e.g., ILHV and
SLEV) or humans (dengue viruses,
yellow fever virus), thereby potential-
ly diminishing disease caused by a
newly introduced flavivirus such as
WNV. Although ILHV infection has
not been detected in Venezuela, this
flavivirus is prevalent in Brazil, Peru,
French Guyana, Trinidad, and
Colombia. Our study demonstrated
widespread distribution of ILHV in
Venezuela. Other South American fla-
viviruses, such as Bussuquara,
Cacipacore, and Iguape, and as yet
undiscovered viruses may also circu-
late in Venezuela. 
We encourage those involved in
the public and animal health systems
in Venezuela to consider zoonotic fla-
viviruses in the differential diagnoses
of human and equine cases of
encephalitis and to consider ecologic
surveillance for zoonotic flaviviruses
in mosquito and vertebrate host popu-
lations. We recommend monitoring
blood and organ donations for fla-
vivirus infections. Our study sheds
light on flavivirus distribution in
Venezuela. However, nothing else is
known about the ecology of zoonotic
flaviviruses in this country. Such
knowledge will be essential for
designing effective surveillance and
control should these viruses be shown
to cause human illnesses.
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Figure. West Nile virus (WNV) collection sites in Venezuela, indicated by number (see
online Appendix Table). Symbols represent results of tests for specific antibodies to WNV
in serum samples of birds and horses (viral titers in a 90% plaque reduction neutralization
test >40 and a 4-fold differential inhibition in a neutralization assay to WNV compared with
other related flaviviruses). Source: Instituto Geográfico de Venezuela Simón Bolivar,
Caracas.LETTERS
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Novel Extended-
spectrum 
β β-Lactamase in
Shigella sonnei
To the Editor: A 38-year-old
French man with a history of chronic
juvenile arthritis was referred to the
Necker-Enfants Malades University
hospital (Paris, France) with a dysen-
teric syndrome. The patient had
returned the day before from a 1-
month stay in Port-au-Prince, Haiti,
where he spent most of his time in
close contact with young children
from an orphanage, most of whom
had diarrhea. Clinical examination at
admission showed fever (39°C),
chills, diffuse abdominal pain, bloody
diarrhea, and vomiting. The patient
received ceftriaxone, which was
stopped on day 4 because initial blood
and stool cultures were negative for
pathogens and clinical signs had com-
pletely resolved. 
Ten days later, he reported the
recurrence of diarrhea without fever.
A novel stool culture grew Shigella
sonnei. An extended-spectrum β-lac-
tamase (ESBL) was detected by dou-
ble-disk synergy test; the isolate was
also resistant to aminoglycosides
(except amikacin), tetracycline, and
cotrimoxazole. The strain was suscep-
tible to fluoroquinolones and fos-
fomycin. It also appeared susceptible
to azithromycin (MIC 4 µg/mL),
although azithromycin MIC for
Shigella spp. should be interpreted
with caution (1). The patient was suc-
cessfully treated with azithromycin at
a dose of 500 mg/day for 5 days.
Azithromycin was preferred to fluoro-
quinolones to avoid the risk for
tendinopathy because of the patient’s
history of chronic juvenile arthritis
and because this antimicrobial agent
was shown to be effective in the treat-
ment of shigellosis caused by mul-
tidrug-resistant strains (2). 
To identify the molecular basis of
this ESBL, a series of PCR primers
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1Deceased.